The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Johnny Mahlangu, BSc, MBBCH, Mmed, FCPath
Professor of Haematology at the University of Witwatersrand, Johannesburg, South Africa
Johnny Mahlangu is a Professor of Haematology in the Faculty of Health Sciences of the University of the Witwatersrand and the National Health Laboratory Service and a Consultant Clinical Haematologist in Charge of Haematology at the Charlotte Maxeke Johannesburg Academic Hospital. Prof Mahlangu received his undergraduate and postgraduate training in science and medicine at the University of the Witwatersrand with haematology specialist and clinical haematology sub-specialist qualifications through the Colleges of Medicine of South Africa. His main area of research is novel therapies in bleeding disorders in which he has served as Principal Investigator for many international multicentre studies. He has published many peer review journal articles and presented many oral talks and posters at national and international scientific meetings.
Prof Mahlangu is currently the President of the College of Pathologists in South Africa and Chairman of the South African Medical Research Council Board. He is a recipient of many awards, the most recent include the Wits University Vice-Chancellor Academic citizenship award in 2018, the American Society of Haematology Global Capacity Building award in 2019, the Publons top 1% cross-field reviewer award in 2019, Wits University Vice-Chancellor Research award in 2020 and an elected member of the Academy of Science of South Africa in 2020, the International Society on Thrombosis and Haemostasis Esteemed Career award in 2021.
Consultant Haematologist, Royal Hallamshire Hospital, Sheffield, UK
Dr. Kingsley Hampton graduated from the University of Leeds with a first-class BSc in Biochemistry and MB ChB with honours. He was a Welcome Research Fellow on the professorial Medical Unit at Leeds General Infirmary and gained an MD in Hormonal Control of Coagulation and fibrinolysis.
Dr. Hampton was trained in Haematology at the University of Sheffield and was appointed Consultant Haematologist and Director of the Arthur Bloom Comprehensive Care Haemophilia Centre at the University Hospital of Wales, Cardiff in 1995. Two years later he returned to the University of Sheffield as a Senior Lecturer and Honorary Consultant Haematologist where he combines an interest in Haemostasis with roles in Undergraduate and Postgraduate Medical Education.
Hermann Eichler, MD
Professor of Transfusion Medicine and Clinical Haemostaseology, Saarland University, Wuerzburg, Germany.
Dr Hermann Eichler completed his medical degree at the University of Wuerzburg, Germany. He performed clinical training in Paediatrics and Anaesthesiology in Wuerzburg and Frankfurt, followed by clinical and scientific training in Transfusion Medicine at the University hospitals in Marburg and Mannheim. In 2005, he finalized his postdoctoral qualification at Heidelberg University.
Dr Eichler took over the position as Professor of Transfusion Medicine and Clinical Haemostaseology at the Saarland University in 2006. He is the head of a certified Haemophilia Comprehensive Care Centre, and his primary scientific interest is focused on patients with congenital and acquired coagulation disorders. His research group is involved in clinical phase I to IV studies and in basic scientific studies on blood coagulation.